FOR IMMEDIATE RELEASE
Project PROTECT Milestone: Angels for Change and Mark Cuban Cost Plus Drug Company have Strengthened the U.S. Supply of Carboplatin & Methotrexate
TAMPA, FL – February 19, 2026 – Angels for Change today announced that the Mark Cuban Cost Plus Drug Company has completed the Preparation and Protective phases of Project PROTECT for Carboplatin Injection and Methotrexate Injection—two essential oncology medicines currently in nationwide shortage. This milestone strengthens onshore readiness and improves supply availability for patients across the United States.
Carboplatin and Methotrexate are used across frontline cancer care, including treatment of ovarian, breast, lung, and pediatric cancers. Ensuring stable access is critical for preventing treatment delays that can compromise outcomes, particularly for patients on time-sensitive chemotherapy regimens.
This update follows the 2025 Project PROTECT grant announcement and reflects proactive action to expand domestic capacity for essential cancer medications. Completing these phases reinforces early preparedness and helps hospitals maintain uninterrupted access during ongoing national shortages.
“This milestone proves that when patients lead the way, real change follows,” said Laura Bray, Founder and Chief Change Maker of Angels for Change. “Acting early with leaders like Mark Cuban Cost Plus strengthens the US supply chain so patients aren’t left waiting for lifesaving medicine.”
Strengthening the Medicine Supply Chain Against Shortages
Launched in 2022, Project PROTECT is a national initiative that funds proactive production of essential medicines at risk of shortage. Through grassroots support, Angels for Change has advanced 13 medications vulnerable to shortage; nine are now market-ready, and three have already been deployed during national shortage events—helping protect more than 750,000 patient treatments.
With support from the 2025 Project PROTECT grant, the Mark Cuban Cost Plus Drug Company has completed key production-readiness milestones for Carboplatin and Methotrexate. These achievements help stabilize U.S. supply for cancer patients and reinforce national preparedness for critical oncology treatments.
“These medications are essential to cancer care, and proactive readiness ensures patients can continue treatment without interruption,” said Alex Oshmyansky, Founder and CEO of Mark Cuban Cost Plus Drug Company. “We are proud to partner with Angels for Change to strengthen supply resilience before patients feel the impact of a shortage.”
Reliable access to Carboplatin and Methotrexate is vital for both adult and pediatric oncology programs. Strengthening onshore readiness for these medicines helps ensure hospitals can deliver uninterrupted, life-saving care when national shortages occur.
About Project PROTECT
Project PROTECT is a national program that provides grants to U.S.-based 503B outsourcing facilities to proactively manufacture essential medications at risk of shortage. By establishing ready-to-activate domestic capacity, the program strengthens national preparedness and protects patient access to vulnerable therapies.
About Angels for Change
Angels for Change is a nonprofit patient-advocacy organization dedicated to ending drug shortages through advocacy, awareness, and strengthening the resilience of the pharmaceutical supply chain. As the operator of the nation’s only Drug Shortage Hotline, Angels for Change partners across healthcare, supply chain, manufacturing, and government to ensure patients receive lifesaving medicines when they need them.
About Mark Cuban Cost Plus Drug Company
The Mark Cuban Cost Plus Drug Company is committed to improving access to affordable medicines by offering transparently priced, low-cost medications. The company partners directly with manufacturers to strengthen the pharmaceutical supply chain and reduce barriers to care.